[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-459394-105":59,"doc-detail-459394-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nanotechnology-in-skin-cancer-therapy-recent-progress-in-targeted-delivery","Nanotechnology in Skin Cancer Therapy: Recent Progress in Targeted Delivery","","Skin cancer, including melanoma and non-melanoma types, remains a major global public-health challenge. Conventional modalities such as surgery, radiotherapy, chemotherapy, and immunotherapy are limited by insufficient skin penetration, systemic toxicity, and frequent recurrence. Nanotechnology is presented as a strategy to improve drug delivery through enhanced tumor accumulation and reduced off-target effects, leveraging nanocarrier platforms including liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and biomimetic systems. The review also discusses applications spanning chemotherapy, photothermal/photodynamic therapy, gene/RNA delivery, and immunotherapy, while addressing key translation barriers such as limited dermal penetration, tumor heterogeneity, immune clearance, and regulatory constraints.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanotechnology-in-skin-cancer-therapy-recent-progress-in-targeted-delivery/459394/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanotechnology-in-skin-cancer-therapy-recent-progress-in-targeted-delivery/459394.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are conventional skin cancer therapies limited in many patients?","Question",{"text":113,"@type":114},"They face poor skin penetration, systemic toxicity, and high recurrence rates, which can reduce effectiveness and tolerability.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does nanotechnology improve targeted drug delivery in skin cancer?",{"text":118,"@type":114},"Nanocarriers enable passive, active, and stimuli-responsive targeting, improving tumor distribution and precision while reducing off-target effects.",{"name":120,"@type":111,"acceptedAnswer":121},"What major challenges remain for translating nanotechnology approaches to the clinic?",{"text":122,"@type":114},"Key barriers include limited dermal penetration, tumor heterogeneity, immune clearance, manufacturing and batch consistency issues, long-term biosafety, and regulatory constraints.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},459394,1790796669,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","The Kaohsiung Journal of Medical Sciences  \nNanotechnology in Skin Cancer Therapy: Recent Progress in Targeted Delivery  \nHuang-Ping Yu1,2 | Ching-Yun Hsu3,4 | Jia-You Fang1,4,5 | Zih-Chan Lin6  \n1Department of Anesthesiology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan | 2School of Medicine, College of Medicine, Chang  \nGung University, Taoyuan, Taiwan | 3Department of Nutrition and Health Sciences, Chang Gung University of Science and Technology, Taoyuan, Taiwan | 4Research Center for Food and Cosmetic Safety and Center for Drug Research and Development, Chang Gung University of Science and Technology, Taoyuan, Taiwan | 5Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Taoyuan, Taiwan | 6Chronic  \nDiseases and Health Promotion Research Center, Chang Gung University of Science and Technology, Chiayi, Taiwan Correspondence: Jia-You Fang ([fajy@mail.cgu.edu.tw](fajy@mail.cgu.edu.tw)) | Zih-Chan Lin ([zclin@mail.cgust.edu.tw](zclin@mail.cgust.edu.tw))  \nReceived: 11 September 2025 | Revised: 30 September 2025 | Accepted: 3 October 2025  \nFunding: This work was supported by Chang Gung Memorial Hospital (CMRPG3P0721-3) and Chang Gung University of Science and Technology (ZRRPF6N0011) .  \nKeywords: anticancer drug | drug targeting | nanocarrier | nanomedicine | skin cancer  \nABSTRACT  \nSkin cancer, encompassing melanoma and non-melanoma types, remains a significant public health concern globally. Conventional therapies—such as surgery, radiotherapy, chemotherapy, and immunotherapy—are constrained by poor skin penetration, systemic toxicity, and high recurrence rates. Nanotechnology has emerged as a promising strategy to address these limitations through enhanced drug delivery, targeted tumor accumulation, and reduced off-target effects. This review summarizes recent advances in nanocarrier-based approaches for skin cancer therapy. Key platforms include liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and biomimetic systems. These nanocarriers facilitate passive, active, and stimuliresponsive targeting, thereby improving drug distribution within tumors and enhancing therapeutic precision. Applications include chemotherapy, photothermal and photodynamic therapy, gene and RNA delivery, and immunotherapy. Despite substantial preclinical success, challenges persist in translating findings to the clinic. These include limited dermal penetration, tumor heterogeneity, immune clearance, and regulatory barriers. Innovative solutions—such as multifunctional nanocarriers, personalized formulations, and non-invasive delivery devices—are being investigated to address these issues. In conclusion, nanotechnology holds considerable potential to transform skin cancer treatment. Continued interdisciplinary efforts are crucial for translating laboratory innovations into clinically viable therapies, ensuring safer and more effective outcomes for patients.  \n1 | Introduction  \n1.1 | Skin Cancer Epidemiology  \nSkin cancer, comprising melanoma (MSC) and non-melanoma skin cancers (NMSCs) such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), represents a major global health burden with an increasing incidence across all regions (Figure 1) . Although MSC accounts for a smaller proportion of  \nskin cancers, it is more aggressive and associated with significantly higher mortality. According to GLOBOCAN 2020, there were over 324,000 new cases of melanoma and more than 57,000 related deaths, with the highest incidence observed in Europe and Oceania, particularly among fair-skinned populations [1] . In contrast, NMSCs—especially BCC—are estimated to be 18–20 times more common than melanoma and are the most frequently diagnosed cancers among light-skinned individuals [2, 3] . While BCC rarely metastasizes, SCC accounts for the  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any ","cbCaiguwtKybxlrJ","https://ap.wps.com/l/cbCaiguwtKybxlrJ","pdf",1354214,11,"English","# Introduction\n## Skin Cancer Epidemiology","[{\"question\":\"Why are conventional skin cancer therapies limited in many patients?\",\"answer\":\"They face poor skin penetration, systemic toxicity, and high recurrence rates, which can reduce effectiveness and tolerability.\"},{\"question\":\"How does nanotechnology improve targeted drug delivery in skin cancer?\",\"answer\":\"Nanocarriers enable passive, active, and stimuli-responsive targeting, improving tumor distribution and precision while reducing off-target effects.\"},{\"question\":\"What major challenges remain for translating nanotechnology approaches to the clinic?\",\"answer\":\"Key barriers include limited dermal penetration, tumor heterogeneity, immune clearance, manufacturing and batch consistency issues, long-term biosafety, and regulatory constraints.\"}]","Nanotechnology in Skin Cancer Therapy: Recent Progress in Targeted Delivery | PDF",1790755843,28]